We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Plants Provide Diagnostic Reagent for West Nile Virus

By LabMedica International staff writers
Posted on 15 Nov 2012
A method has been developed for testing for West Nile Virus (WNV), using plants to produce biological reagents for detection and diagnosis. More...


A plant expression system has been investigated for protein production due to its low-cost and high-scalability nature and its ability to make appropriate posttranslational modifications.
Scientists at Arizona State University (Tempe, AZ, USA) explored the feasibility of using plant transient expression systems to produce two groups of protein reagents that are required for the detection and diagnosis of WNV infection. One was a recombinant antigen derived from the domain III (DIII) of WNV envelope (E) protein and the second, a monoclonal antibody (mAb E16) that specifically recognizes WNV DIII.

High expression levels of both reagents were observed in two kinds of plants: Nicotiana benthamiana, which is a close relative of tobacco, and lettuce. The two reagents may be readily purified to greater than 95% and retain their native functionality and specificity. The binding specificity of plant-derived E16 at various concentrations of this mAb were incubated with either DIII of WNV or DIII of Dengue virus serotype 2 (DENV-2) that was immobilized on an enzyme linked immunosorbent assay (ELISA) plate. A mammalian cell-culture-derived E16 and a generic human immunoglobulin G (IgG) (Southern Biotech, Birmingham, AL, USA) were used as the positive and negative control, respectively.

The binding to WNV DIII increased with the concentration of lettuce or N. benthamiana-derived E16 in the reaction in a similar manner as the mammalian cell-derived E16 positive control. In contrast, none of the E16s showed specific binding to DIII of DENV-2. The negative control, a generic human IgG, showed no specific binding to either WNV or DENV-2 DIII. These results indicate that the specific avidity for WNV DIII is retained by the plant-derived E16s. This high specificity makes it a valuable reagent in obtaining unambiguous diagnostic results for detecting WNV and WNV infection.

Qiang Chen, PhD, the senior author said, “Our test will improve the accuracy of diagnosis, leading to the proper treatment of patients affected by WNV. The plant-derived monoclonal antibody we examined is not only low-cost, but highly specific for WNV antigen and does not recognize antigens from other flaviviruses.” The study was published in the October 2012 issue of the Journal of Biomedicine and Biotechnology.

Related Links:
Arizona State University
Southern Biotech


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.